Remix Therapeutics’ $70 Million Series B Financing

Gunderson Dettmer advised Remix Therapeutics on the deal.Remix Therapeutics, a Massachusetts-based biotech company, announced its $70 million Series B financing which included participation from Surveyor, Foresite Capital,…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

This content is for Standard 1 Year members only.
Login Join Now